Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

PHASE3RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions

Type 2 Diabetes

Interventions

DRUG

HRS953

HRS953-low dose

DRUG

HRS953

HRS953-high dose

DRUG

Placebo

Trial Locations (1)

RECRUITING

Perking University Peoples' Hospital, Beijing

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY